Marinomed Biotech AG Logo

Marinomed Biotech AG

Develops virus-blocking products & immunology therapies via proprietary technology platforms.

MARI | VI

Overview

Corporate Details

ISIN(s):
ATMARINOMED6
LEI:
529900GN3B1EN80XF405
Country:
Austria
Address:
Hovengasse 25, 2100 Korneuburg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Marinomed Biotech AG is a science-based biopharmaceutical company that develops innovative therapies for diseases in virology and immunology. The company leverages two proprietary technology platforms: Carragelose®, a virus-blocking compound used in globally marketed nasal sprays and lozenges, and Marinosolv®, a technology platform that enhances the solubility of poorly soluble compounds to develop new treatments for various immunological conditions. Marinomed's business model encompasses in-house development of medicinal products and medical devices, as well as strategic partnerships to commercialize its pipeline and technologies. The company focuses on addressing conditions with limited or no effective treatment options, particularly in respiratory and autoreactive immune disorders.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-06 14:58
Regulatory News Service
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Mari…
English 34.6 KB
2025-10-06 14:58
M&A Activity
EQS-Adhoc: Marinomed Biotech AG startet Prüfung strategischer Optionen für die …
German 36.4 KB
2025-10-06 14:56
Regulatory News Service
Marinomed Biotech AG begins reviewing strategic options for the Marinosolv plat…
English 11.1 KB
2025-09-17 13:48
Earnings Release
Marinomed Biotech AG announces results for the first half year of 2025
English 10.6 KB
2025-09-17 13:42
Interim Report
EQS-AFR: Marinomed Biotech AG: Release of a Financial report
English 3.4 MB
2025-09-17 13:42
Interim Report
EQS-AFR: Marinomed Biotech AG: Bekanntmachung über die Veröffentlichung eines F…
German 3.5 MB
2025-09-16 15:24
Share Issue/Capital Change
EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory s…
English 31.7 KB
2025-09-16 15:24
Share Issue/Capital Change
EQS-Adhoc: Marinomed Biotech AG beschließt Kapitalerhöhung unter Bezugsrechtsau…
German 33.7 KB
2025-09-16 15:22
Share Issue/Capital Change
Marinomed Biotech AG resolves capital increase excluding statutory subscription…
English 8.0 KB
2025-09-02 09:18
Pre-Annual General Meeting Information
EQS-AGM: Marinomed Biotech AG: Convening of an Extraordinary General Meeting fo…
English 51.6 KB
2025-09-02 09:17
Pre-Annual General Meeting Information
EQS-HV: Marinomed Biotech AG: Einberufung einer außerordentlichen Hauptversamml…
German 50.1 KB
2025-09-02 09:16
Pre-Annual General Meeting Information
Marinomed Biotech AG: Convening of an Extraordinary General Meeting for Tuesday…
English 21.9 KB
2025-09-01 11:58
Capital/Financing Update
EQS-Adhoc: Marinomed Biotech AG: Agreement on the key terms of the issue of a s…
English 32.9 KB
2025-09-01 11:57
Capital/Financing Update
EQS-Adhoc: Marinomed Biotech AG: Einigung über die Eckpunkte der Emission einer…
German 33.5 KB
2025-09-01 11:56
Capital/Financing Update
Marinomed Biotech AG: Agreement on the key terms of the issue of a secured EUR …
English 8.7 KB

Automate Your Workflow. Get a real-time feed of all Marinomed Biotech AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Marinomed Biotech AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Marinomed Biotech AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.